Abbvie Inc Dossier
Qualitative Analysis
Business overview
AbbVie Inc. is a global, research-driven biopharmaceutical company focused on developing and marketing advanced therapies across several key therapeutic areas, including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013, the company has successfully navigated the loss of exclusivity of its legacy blockbuster drug Humira. This transition has been driven by the rapid commercial scaling of its next-generation immunology therapies, Skyrizi and Rinvoq, which have established dominant market positions in plaque psoriasis, Crohn's disease, ulcerative colitis, and atopic dermatitis.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Maximizing the market penetration and label expansion of next-generation immunology blockbusters Skyrizi and Rinvoq across 10+ indications to fully offset Humira's biosimilar erosion.
Expected impact: Projecting combined Skyrizi and Rinvoq revenues to surpass $31 billion by 2027, securing long-term category leadership.
Expanding the neuroscience portfolio through late-stage pipeline development and strategic acquisitions, focusing on therapies for schizophrenia, Parkinson's disease, and major depressive disorder.
Expected impact: Targeting approximately $12.5 billion to $12.6 billion in neuroscience revenue for FY2026, driven by Vraylar, Botox Therapeutic, and Vyalev.
Investing in domestic manufacturing infrastructure to support the production of current and next-generation immunology and neuroscience medicines.
Expected impact: Significantly expands drug delivery device manufacturing capabilities and active pharmaceutical ingredient (API) capacity, creating hundreds of jobs.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire Capstan's in vivo CAR-T cell therapy platform, including lead candidate CPTX2309, consolidating ownership of LNP-mRNA technology for B-cell-mediated autoimmune diseases.
Financial impact: Consolidated platform ownership ahead of key clinical readouts, adding to acquired IPR&D expenses.
To access ALIA-1758, an experimental Alzheimer's therapy utilizing a novel blood-brain barrier crossing technology, bolstering AbbVie's neuroscience pipeline.
Financial impact: Diversified the early-to-mid stage neurology pipeline with high-impact potential assets.
To strengthen AbbVie's neuroscience portfolio with late-stage assets including emraclidine (schizophrenia) and tavapadon (Parkinson's disease).
Financial impact: Setback resulted in a substantial non-cash impairment charge, though other assets like tavapadon continue development.